Insmed falls on weak 2025 sales forecast for lead drug

Insmed

20/02/2025 14:55

** Drugmaker Insmed's  INSM.O  shares fall 1.6% to $82.45 
        ** Co 
    forecasts
     2025 revenue of $405 million to $425 million for their drug
Arikayce, compared with analysts' expectations of $433 million
as per data compiled by LSEG  
  
    ** Co reports Q4 revenue of $104.4 million, higher than
analysts' est of $102.8 million, driven by Arikayce which is its
only commercial drug 
    ** The drug is used for treatment of Mycobacterium avium
complex (MAC) lung infections, which commonly affect individuals
with weakened immune systems
     ** Co reports Q4 loss of $1.32/share vs analyst est of
$1.16/share loss
    ** Stock has tripled in the past 12 months  

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))